

*Full Length Research Paper*

# Revisiting the linkage between ethnomedical use and development of new medicines: A novel plant collection strategy towards the discovery of anticancer agents

Joshua M. Henkin<sup>1</sup>, Kongmany Sydara<sup>2</sup>, Mouachanh Xayvue<sup>2</sup>, Onevilay Souliya<sup>2</sup>, A. Douglas Kinghorn<sup>3</sup>, Joanna E. Burdette<sup>1</sup>, Wei-Lun Chen<sup>1</sup>, Bethany G. Elkington<sup>4</sup> and Djaja D. Soejarto<sup>1\*</sup>

<sup>1</sup>Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood St., Chicago, Illinois 60612, USA.

<sup>2</sup>Institute of Traditional Medicine, Ministry of Health, Vientiane Capital, Lao People's Democratic Republic.

<sup>3</sup>Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210, USA.

<sup>4</sup>Science and Education, Field Museum, 1400 S. Lake Shore Drive, Chicago, Illinois 60605, USA.

Received 31 August, 2017; Accepted 3 October, 2017

The Vietnam-Laos International Cooperative Biodiversity Group (ICBG) based at the University of Illinois at Chicago (UIC) catalyzed a country-wide network of medicinal plant preserves (MPP) and medicinal biodiversity preserves (MBP) now established in ten provinces of the Lao People's Democratic Republic (Lao PDR), which are relied upon as protected sources of ethnomedicines for local villagers and traditional healers. In collaboration with the Lao PDR's Institute of Traditional Medicine (ITM), our ongoing P01 Program Project (Ohio State University) examined the anticancer bioprospecting potential for two of the most exhaustively inventoried of these sites: the Bolikhamxay MPP and the Xiengkhouang MBP. Guided by prior voucher specimens sourced from these reserves, with an overwhelming emphasis on plants employed in traditional medicine, 201 distinct samples from 96 species were collected along with proper herbarium documentation. Aliquots of these plant samples were extracted in azeotropic ethanol and evaporated to dryness for initial biological evaluation. In six samples from six different species (2.99% of the collected samples and 6.25% of taxa), it was observed that extracts exhibited notable cytotoxicity against HT-29 colon adenocarcinoma cells. The wisdom behind the utilization of HT-29 cells in this preliminary biological screen is discussed. Furthermore, comparison of screening results based on longstanding considerations and ideological underpinnings of ethnobotanical vs. "random" biodiversity-based collection approaches is detailed herein. The results of this interdisciplinary study support the hypothesis that, by privileging the initial sample set in terms of human safety and pharmacological activity, ethnobotanically driven collection for biological screening efforts can produce leads unprecedented by the strict traditional usages of plants.

**Key words:** Lao People's Democratic Republic (PDR), medicinal plants, traditional medicine, cancer.

## INTRODUCTION

In trusting human agency and the intentionality of traditional ecological knowledge, one may be liable to

conclude that botanical ethnopharmacopeias consist of plants that: (a) bear useful pharmacological activities and

can improve health status and (b) can be administered to patients in ways that render them clinically safe within reasons (Fadeyi et al., 2013; Pan et al., 2013; Getasetegn and Teferi, 2016). Given these two likelihoods, these ethnopharmacopeias can be studied in their entirety through biological screening efforts (Mazzio and Soliman, 2009; Fadeyi et al., 2013; Leonti and Weckerle, 2015; Odonne et al., 2017), setting the stage in the drug discovery pipeline towards human health applications not necessarily anticipated by indigenous knowledge and folk clinical application of the particular plants evaluated in this way. It might even be expected that this strategy could yield results superior to “random” collection efforts constrained to geographic areas with similar levels of species richness and biodiversity (Bletter, 2007; Saslis-Lagoudakis et al., 2012). Prior meta-analysis suggests that on a per sample basis, depending on ethnobotanical use and screening assays performed for samples evaluated from Laos and Vietnam, plants employed in traditional medicine can have a higher hit rate for bioactivity in empirical studies (Gyllenhaal et al., 2012). Although there are caveats and nuances to this finding, which will be discussed subsequently, this insight is worth bearing in mind in the context of the present paper. The hypothesis of this study, accordingly, states that the agentive, purposive nature of botanical ethnopharmacopeias biases sample sets derived from them for useful bioactivity; this selection criterion therefore lends itself to success in initial biological screening and drug discovery studies.

Towards the end of further, and unambiguous exploration of the possibility for ethnobotanically driven screening efforts, in this instance for the preliminary stages of anticancer drug discovery, two of the most extensively inventoried preserves in the Lao PDR, the Xiengkhouang MBP and the Bolikhamxay MPP were selected as promising expedition sites for the extramurally funded Program Project (P01) from among the ten preserves that are extant (Sydara et al., 2014; Soejarto et al., 2015) (Figure 1). These reservoirs for local traditional medicine plants served as the premiere P01 project sites for the exploration of the ethnopharmacopeias of Laos through the lens of this pragmatic, serendipitous-activity-through-human-utility paradigm. This paper presents the results of this endeavor.

## METHODOLOGY

### Memorandum of agreement

A Memorandum of Agreement (MOA) for the conduct of collaborative research targeted to the flowering plants, between the

University of Illinois at Chicago and the Institute of Traditional Medicine (ITM, Vientiane, Lao PDR), covering issues on intellectual property and the sharing of benefits in the event of the discovery and development of a pharmaceutical product was established. This MOA allowed for the collection of plant materials (plant samples and their voucher herbarium specimens) in Laos and their transfer to and biological evaluation in the USA.

### Plant collection

Following the signing of this agreement, a joint plant collection expedition between the University of Illinois at Chicago (UIC) and the Institute of Traditional Medicine (ITM) was undertaken in the Lao PDR. One expedition site was the Xiengkhouang Medicinal Biodiversity Preserve (MBP) of the Kham District, Xiengkhouang Province, and the other was Bolikhamxay Medicinal Plant Preserve (MPP) of the Paksan District, Bolikhamxay Province (Figure 1).

### Xiengkhouang medicinal biodiversity preserve expedition

The Xiengkhouang Medicinal Biodiversity Preserve (MBP) (as depicted in Figure 1) is located at about 50 km northeast of the capital city (Phonsavanh) of Xiengkhouang Province, near Ban Tha, a rural Lao Lum (Lowland Lao) village in the Kham District, and about 15 km from both Muang Kham and Ban Tha. The elevation is approximately 1,140 m above sea level, at 19°43' N; 103°35' E (GPS reading). This preserve comprises approximately 500 hectares of high quality, secondary, montane tropical rainforest (Figure 2).

Two of the ITM's 5-passenger Toyota Hilux pickup trucks, with collapsible soft tops for covering the rear cargo area, provided excellent mobility throughout the expedition period (December 8 to 13, 2015). These vehicles allowed for the transportation of 6 to 10 passengers (including drivers) in addition to the loads of collected plant materials and field supplies. Two workers and several other locals were employed from the village of Ban Tha for the purposes of harvesting and processing plant material.

Near the Xiengkhouang MBP, quarters at the Seng Deuane guest house in Meuang Kham were rented as the expedition base and as equipment and supplies storage. The concrete patio of the guest house served as the base for drying plant samples and working quarters. The space and facilities of this guest house permitted the efficient performance and completion of the expedition within a short time period. The warm and mostly dry conditions in the winter season during the expedition eased the initial stages of processing of the voucher specimens and the plant samples collected.

Part of the supplies and equipment for use in the expedition, such as tarpaulins, rice sacks, nylon mesh bags, cardboard, plant presses, strings, branch cutters, twig clippers, knives (pointed knives known locally as *mid* [/mi:d/]), a GPS, digital cameras, binoculars, used newspapers, and other plant collecting and processing supplies, was brought from Vientiane through the ITM's supplies or as part of the ITM and UIC personnel's belongings. Forays into the field and the search for the plants collected were guided by a list and photographs of plants previously collected (Soejarto et al., 2015) from this MBP. Plant samples and voucher herbarium specimens were collected, carefully numbered and documented by field notes and photographic images. Numbered herbarium specimens were pressed between newspapers in the

\*Corresponding author. E-mail: doelsoejarto@gmail.com.



Towards the end of further, and unambiguously, exploring the possibility for ethnobotanically-driven screening efforts, in this instance for the preliminary stages of anticancer drug discovery, two of the most extensively inventoried preserves in the Lao PDR, the Xiangkhouang MBP and the Bolikhamxay MPP, were selected as promising expedition sites for our Program Project (P01) from among the ten preserves that are extant (Sydara et al., 2014; Soejarto et al., 2015) (Fig. 1). These reservoirs for local traditional medicine plants served as the premiere P01 project sites for the exploration of the ethnopharmacopeias of Laos through the lens of this pragmatic, serendipitous-activity-through-human-utility paradigm. This paper presents the results of this endeavor.

**Figure 1.** Medicinal plants preserve and medicinal biodiversity preserves network of Lao PDR (Soejarto et al., 2015), showing the location of expedition sites described in this paper.

field. Screening samples, 1 to 3 kg fresh weight, depending on nature or fleshiness of the plant material, were packed in sample collection bags made of nylon mesh and were placed in the trucks. On return from the field, these were arranged in rows to dry on the concrete patio of the Seng Deuane guest house, only being removed to the interior of the guest house or a nearby wooden, roofed platform when the conditions were overcast. At the end of the field operation (December 13, 2015), semi-dry samples in the nylon mesh bags were loaded into the trucks, while voucher herbarium specimens in newspapers were cinched in straps and cardboard sheets and also loaded into the trucks. All field equipment and plant materials collected were transported by the pickup trucks to the ITM, where the drying of the samples and voucher herbarium specimens was completed.

#### **Bolikhamxay medicinal plant preserve expedition**

The Bolikhamxay Medicinal Plant Preserve (MPP), also known as the Somsavath MPP due to its propinquity, usefulness and political connection to Somsavath Village, is about 27 km south of Pakxan, the capital city of Bolikhamxay Province and is 163 m above sea level, at 18°27' N; 103°48' E. The preserve comprises approximately 13 hectares of high quality, secondary, lowland broad-leaved tropical rainforests recovering from past fires and logging (Figure 3), with adjoining land cleared for agriculture and plantations, primarily, economic botanicals (*Hevea* rubber, agarwood, etc.).

One of the ITM's 5-passenger Toyota Hilux pickup trucks, with a collapsible soft top for covering the rear cargo area, provided excellent mobility throughout the expedition period (December 14-17, 2015). This vehicle allowed for the transportation of 3 to 5 passengers (including drivers) in addition to the loads of collected plant materials and field supplies. Guest house quarters in Pakxan were rented as the expedition base and as equipment and supplies

storage. The concrete patio and blacktop of the guesthouse served as a base for drying plant samples and working quarters. The space and facilities of this guesthouse permitted the efficient performance and completion of the expedition within a short time period.

As in the Xiangkhouang expedition, part of the supplies and equipment for use in the expedition was brought from Vientiane through the ITM's supplies or as part of the ITM and UIC personnel's belongings. In the collection area, one worker and several other locals were employed from the village of Ban Khampai for the purposes of harvesting and processing plant material. Forays into the field and the search for plants to be collected were guided by a list and by photographs of the plants previously collected (Soejarto et al., 2015) from this MPP. The warm and mostly dry conditions during the winter season of the expedition eased the initial stages of processing for voucher specimens and screening samples in the field. The roofed cement floor of the visitor center, near where the automobiles were usually parked, served as a temporary processing and drying area before the plant materials were loaded into the cargo bay of the Toyota Hilux on returning to the Pakxan guesthouse.

Plant samples and voucher herbarium specimens were carefully numbered and documented by field notes and photographic images. Numbered herbarium specimens were pressed between newspapers in the field. Screening samples, 1 to 3 kg fresh weight, depending on nature or fleshiness of the plant material, were packed in sample collection bags made of nylon mesh and were placed in the truck during forays. Later these were arranged in rows on the concrete patio of the guesthouse. At the end of the field operation (December 17, 2015), semi-dry samples in the nylon mesh bags were loaded into the truck, while voucher herbarium specimens in newspapers were cinched in straps and cardboard sheets. All were transported by the pickup truck to the ITM, where the drying of the samples and voucher herbarium specimens was completed.





**Figure 2.** Xiangkhouang Medicinal Biodiversity Preserve, December 9-11, 2015. Top left: Roadside signage downslope of the expedition site. Top right: View of the montane tropical rainforest on a cloudy day with forbs and soil in the foreground. Bottom left: View of the tree cover from the roadside. Bottom right: Forested rivulet within the preserve.

### Plant identification

One set of voucher herbarium specimens was shipped, processed and accessioned at the John G. Searle Herbarium of the Field Museum of Natural History (F), Chicago. Two additional sets of vouchers were deposited at the herbaria of the ITM. Taxonomic identification of the plants collected was initially performed (by JMH, KS, OS, MX, DDS) at the ITM Herbarium and was completed at the herbarium of the Field Museum.

### Plant extraction

Azeotropic ethanolic extracts of the plant samples were generated from 30 g aliquots of plant samples at the laboratories of the ITM. Hence, 30 g aliquots of the 201 unground plant samples were milled and subsequently macerated twice overnight in 250 ml, followed by 200 ml of solvent, successively. The pooled extracts from each sample were desiccated by rotary evaporation at 40°C and transferred to small vials for shipment. All extracts were dispatched to and received safely at the University of Illinois at Chicago, where they were submitted to the MTS assay to determine their effect on the viability of HT-29 colon adenocarcinoma cells.

### Colorimetric MTS assay for cell viability

Human colon cancer cells HT-29 were purchased from the

American Type Culture Collection (Manassas, VA). The cell line was propagated at 37°C in 5% CO<sub>2</sub> in RPMI 1640 medium, supplemented with fetal bovine serum (10%), penicillin (100 units/ml), and streptomycin (100 µg/ml). Cells in log phase growth were harvested by trypsinization followed by two washings to remove all traces of the enzyme. A total of 5,000 cells were seeded per well of a 96-well clear, flat-bottom plate (Microtest 96®, Falcon) and incubated overnight (37°C in 5% CO<sub>2</sub>). Samples dissolved in DMSO were then diluted and added to the appropriate wells (concentrations: 20 and 2 µg/ml; total volume: 100 µl; DMSO: 0.5%). The cells were incubated in the presence of test substance for 72 h at 37°C and evaluated for viability with a commercial absorbance assay (CellTiter 96® Aqueous One Solution Cell Proliferation Assay, Promega Corp Promega) measured viable cells. Survival percentage, based on microplate reader (Synergy Mx, BioTek) readings of absorbance at 490 nm, was expressed in percentage relative to the solvent (DMSO) control. One of the authors (Dr. Wei-Lun Chen) performed the bioassay and interpreted the results (Ren et al., 2017).

## RESULTS

### Fieldwork

A total of 201 plant samples for preliminary biological screening, comprising 96 species of seed plants,



**Figure 3.** Bolikhamxay Medicinal Plant Preserve, December 15-16, 2015. Top left: Roadside signage at the entrance of the preserve. Top right: View from the road of the path into the preserve, on left. Bottom left: Processing samples on the patio of the pavilion near the entrance. Bottom right: Lowland tropical rainforest within the preserve featuring trees, treelets, lianas, and forbs.

documented by 96 sets of voucher herbarium specimens, were gathered during the two expeditions (Table 1).

### MTS assay

At least six samples out of the 201 collected presented with activity bearing enough interest for further testing with HT-29 colon adenocarcinoma cells, using the colorimetric MTS assay for cell viability, that is, cytotoxicity. At the 20  $\mu\text{g/ml}$  incubation condition, less than 60% of the HT-29 cells in these samples survived, and in five out of six of these samples, less than 50% of the HT-29 cells survived, indicating that the  $\text{IC}_{50}$  of these five extracts should be under 20  $\mu\text{g/ml}$ . Given that all six samples were from different taxa, this means that 2.99% of the collected samples and 6.25% of taxa with samples that were screened in this way were sufficiently cytotoxic to merit initial recollection for further studies.

The six samples of interest (Table 2 and Figure 4) are the following: the stem material of *Cryptolepis dubia* (Burm.f.) M.R.Almeida (A07194/ST; Asclepiadaceae); the aerial parts of *Rubia argyi* (H.Lév. & Vaniot) Hara ex Lauener (A07196/PX; Rubiaceae); the fruits of *Reevesia pubescens* Mast. (A07214/FR; Sterculiaceae); the combined leaves, twigs, and fruits of *Maclura tricuspidata* Carrière (A07257/LF+TW+FR; Moraceae); the stem material of *Millettia pachyloba* Drake (A07338/ST; Fabaceae-Papilionoideae); and the leaves and twigs of *Gardenia annamensis* Pit. (A07365/LF+TW; Rubiaceae).

### DISCUSSION

#### Usage of HT-29 and other human tumor cell lines in anticancer screening of plants

The prevalence of cytotoxic taxa in this sample set





**Figure 4.** Plants from the Xiengkhouang Medicinal Biodiversity Preserve with samples exhibiting notable cytotoxicity in HT-29 colon adenocarcinoma cells. A: *Cryptolepis dubia*. B: *Rubia argyi*. C: *Reevesia pubescens*. D: *Maclura tricuspidata*. E: *Millettia pachyloba*. F: *Gardenia annamensis*.

derived from two expeditions in the Lao PDR is generally consistent with the results anticipated by the laboratory personnel of the P01CA125066 grant (Kinghorn et al., 2009, 2016). The HT-29 cell line was selected as the sole gatekeeper for initial cytotoxicity testing, from amongst a number of human tumor cell lines accessible to Ohio State University scientists involved with the program project. HT-29 was the only human tumor cell line on hand that displayed high selectivity for the most cytotoxic extracts through its low susceptibility, with unpublished, internal project data suggesting that a signature of only ~5% (or less) of sample extracts evaluated bore significant activity against HT-29 cells. In terms of the P01 project itself, the consequent focus on HT-29 cells and human colon adenocarcinoma by association has led to screening for inhibitory activity in the *K-ras* pathway, becoming one of the major mechanistic assays emphasized (Peruchot et al., 1987; Ren et al., 2014). HT-29 cells are also significant in that the cell line has long been and continues to be included in the NCI-60 panel utilized for the COMPARE algorithm to predict mechanism of action for cytotoxic compounds (Paull et al., 1989; Shoemaker, 2006). More broadly HT-29 cells are derived from a human colon adenocarcinoma, and this subtype of colon cancer, derived from the epithelial lining surrounding the lumen of the large intestine, is responsible for over 90% of colon cancer cases (Kumar et al., 2010). According to the most current data from the

Center for Disease Control, furnished with the assistance of the National Cancer Institute, as of 2013 colorectal cancer is the third most prevalent cancer shared by both sexes in the United States of America and is the second deadliest (Center for Disease Control, 2014).

Aside from the P01 project's established reasoning for proceeding first with cytotoxicity screening using HT-29 cells under the aegis of the National Cancer Institute, the results of this initial P01 expedition and bioassay work in the Lao PDR also show reasonable consistency with prior bio-prospecting findings of the Vietnam-Laos ICBG project (1998-2012) (Gyllenhaal et al., 2012). It should be noted that the National Cooperative Drug Discovery Group ("Novel Strategies for the Discovery of Plant-Derived Anticancer Agents") (Kinghorn et al., 2003; Balunas et al., 2006), the intellectual predecessor of the P01CA125066 program project, overlaps substantially with the Vietnam-Laos ICBG (Kinghorn et al., 2003, 2009) in both time period (1990-2006) and the cell lines employed in cytotoxicity testing. Cell lines tested for viability against plant extracts during the ICBG included human colon cancer (COL-2), human promyelocytic leukemia (HL-60), human telomerase reverse transcriptase-retinal pigment epithelial cells (hTERT-RPE1), human umbilical vein endothelial cells (HUVEC), human cervical carcinoma, formerly believed to be oral carcinoma (KB); human prostate carcinoma (LNCaP), human lung cancer (LU-1), and human breast cancer

**Table 1.** Plant samples from the December 2015 P01 expeditions in the Lao PDR, listed in order of their voucher herbarium collection and by their scientific name (species-family), number and part of the plant of the primary screening samples, and locations.

Voucher herbarium specimen	Species (Family) <sup>a</sup>	Primary samples (Plant parts)	Collection location
JMH 001	<i>Medinilla septentrionalis</i> (W.W. Sm.) H.L. Li (Melastomataceae)	A07186/ST; A07187/RT; A07188/LF+TW+FL+FR	Xiengkhouang MBP
JMH 003	<i>Micromelum falcatum</i> (Lour.) Tanaka (Rutaceae)	A07189/RT; A07190/ST; A07191/LF+TW+FR	Xiengkhouang MBP
JMH 004	<i>Derris scandens</i> (Roxb.) Benth. (Fabaceae-Papilionoideae)	A07192/ST; A07193/LF+TW	Xiengkhouang MBP
JMH 005	<i>Cryptolepis dubia</i> (Burm.f.) M.R. Almeida (Asclepiadaceae)	A07194/ST; A07195/LF+TW	Xiengkhouang MBP
JMH 006	<i>Rubia argyi</i> (H.Lév. & Van.) Hara ex Lauener (Rubiaceae)	A07196/PX	Xiengkhouang MBP
JMH 008	<i>Actinodaphne rehderiana</i> (C.K. Allen) Kosterm. (Lauraceae)	A07197/ST; A07198/LF+TW	Xiengkhouang MBP
JMH 009	<i>Cissampelos pareira</i> L. (Menispermaceae)	A07199/PX	Xiengkhouang MBP
JMH 010	<i>Clematis leschenaultiana</i> DC. (Ranunculaceae)	A07200/PX	Xiengkhouang MBP
JMH 011	<i>Vitex quinata</i> (Lour.) F.N. Williams (Verbenaceae)	A07201/FR; A07202/LF+TW; A07203/ST	Xiengkhouang MBP
JMH 012	<i>Schefflera cf. leucantha</i> R. Vig. (Araliaceae)	A07204/FR+TW; A07205/LF+TW; A07206/ST	Xiengkhouang MBP
JMH 013	<i>Elsholtzia blanda</i> (Benth.) Benth. (Lamiaceae)	A07207/PX	Xiengkhouang MBP
JMH 014	<i>Saurauia napaulensis</i> DC. (Actinidiaceae)	A07208/FR+TW; A07209/LF+TW	Xiengkhouang MBP
JMH 016	<i>Clematis subumbellata</i> Kurz (Ranunculaceae)	A07210/PX	Xiengkhouang MBP
JMH 017	<i>Mucuna bracteata</i> DC. (Fabaceae-Papilionoideae)	A07211/PX	Xiengkhouang MBP
JMH 018	<i>Ilex</i> sp. (Aquifoliaceae)	A07212/ST; A07213/LF+TW+FR	Xiengkhouang MBP
JMH 021	<i>Reevesia pubescens</i> Mast. (Sterculiaceae)	A07214/FR; A07215/LF+TW; A07216/ST	Xiengkhouang MBP
JMH 022	<i>Schima wallichii</i> (DC.) Korth. (Theaceae)	A07217/LF+TW+FR; A07218/ST	Xiengkhouang MBP
JMH 023	<i>Rourea minor</i> (Gaertn.) Alston (Connaraceae)	A07219/ST; A07220/LF+TW; A07221/FR	Xiengkhouang MBP
JMH 024	<i>Acacia pennata</i> (L.) Willd. (Fabaceae-Mimosoideae)	A07222/FR; A07223/LF+TW; A07224/ST	Xiengkhouang MBP
JMH 025	<i>Wendlandia uvariifolia</i> Hance ssp. <i>laotica</i> (Pit.) Cowan (Rubiaceae)	A07225/FR; A07226/LF+TW	Xiengkhouang MBP
JMH 026	<i>Wikstroemia meyeniana</i> Warb. (Thymelaeaceae)	A07227/ST; A07228/RT; A07229/LF+TW+FR	Xiengkhouang MBP
JMH 027	<i>Engelhardia roxburghiana</i> Wall. (Juglandaceae)	A07230/SB; A07231/LF+TW+FR; A07232/SW	Xiengkhouang MBP
JMH 028	<i>Rhus chinensis</i> Mill. (Anacardiaceae)	A07233/LF+TW+FR	Xiengkhouang MBP
JMH 029	<i>Rothea serrata</i> (L.) Steane & Mabb. (Verbenaceae)	A07234/LF+TW+FL; A07235/ST	Xiengkhouang MBP
JMH 030	<i>Vernonia arborea</i> Buch.-Ham. (Asteraceae)	A07236/LF+FL; A07237/ST	Xiengkhouang MBP
JMH 031	<i>Uncaria sessilifructus</i> Roxb. (Rubiaceae)	A07238/LF+TW+FL; A07239/ST	Xiengkhouang MBP
JMH 032	<i>Debregeasia longifolia</i> (Burm.f.) Wedd. (Urticaceae)	A07240/LF+TW+FR; A07241/ST	Xiengkhouang MBP
JMH 036	(Lamiaceae?)	A07242/PX	Xiengkhouang MBP
JMH 037	<i>Casearia graveolens</i> Dalzell (Flacourtiaceae)	A07243/LF+TW+FR; A07244/ST	Xiengkhouang MBP
JMH 038	<i>Pittosporum napaulense</i> (DC.) Rehder & E.H. Wilson (Pittosporaceae)	A07245/LF+TW+FR; A07246/ST	Xiengkhouang MBP
JMH 039	<i>Eurya laotica</i> Gagnep. (Theaceae)	A07247/LF+TW+FR; A07248/ST	Xiengkhouang MBP
JMH 040	<i>Melastoma imbricatum</i> Wall. ex Triana (Melastomataceae)	A07249/LF+TW; A07250/ST	Xiengkhouang MBP
JMH 041	<i>Rubus alceifolius</i> Poir. (Rosaceae)	A07251/LF+TW; A07252/ST	Xiengkhouang MBP
JMH 042	<i>Rubus pluribracteatus</i> L.T.Lu & Boufford (Rosaceae)	A07253/LF+TW; A07254/ST	Xiengkhouang MBP
JMH 043	<i>Ligustrum sinense</i> Lour. (Oleaceae)	A07255/LF+TW; A07256/ST	Xiengkhouang MBP

Table 1. Cont'd.

JMH 044	<i>Maclura tricuspidata</i> Carrière (Moraceae)	A07257/LF+TW+FR; A07258/ST	Xiengkhouang MBP
JMH 045	<i>Elephantopus mollis</i> Kunth (Asteraceae)	A07259/PL	Xiengkhouang MBP
JMH 046	<i>Tadehagi triquetrum</i> (L.) H. Ohashi (Fabaceae-Papilionoideae)	A07260/PL	Xiengkhouang MBP
JMH 048	<i>Itea macrophylla</i> Wall. (Iteaceae)	A07261/LF+TW+FR; A07262/SB; A07263/SW	Xiengkhouang MBP
JMH 049	<i>Rhynchosyche ellipticum</i> (Wall. ex D. Dietr.) A. DC. (Gesneriaceae)	A07264/LF+FR; A07265/ST	Xiengkhouang MBP
JMH 052	<i>Symplocos lancifolia</i> Sieb. & Zucc. (Symplocaceae)	A07266/LF+TW; A07267/SB; A07268/SW	Xiengkhouang MBP
JMH 053	<i>Chloranthus spicatus</i> (Thunb.) Makino (Chloranthaceae)	A07269/PX	Xiengkhouang MBP
JMH 055	<i>Buddleja asiatica</i> Lour. (Buddlejaceae)	A07270/LF+TW+FL; A07271/ST	Xiengkhouang MBP
JMH 057	<i>Cayratia tenuifolia</i> (Wight & Arn.) Gagnep. (Vitaceae)	A07272/LF+TW+FR; A07273/ST	Xiengkhouang MBP
JMH 058	<i>Oreocnide integrifolia</i> (Gaudich.) Miq. (Urticaceae)	A07274/LF+TW+FR; A07275/ST	Xiengkhouang MBP
JMH 059	<i>Gynura divaricata</i> (L.) DC. (Asteraceae)	A07276/PX	Xiengkhouang MBP
JMH 060	<i>Deeringia amaranthoides</i> (Lam.) Merr. (Rosaceae)	A07277/PX	Xiengkhouang MBP
JMH 061	<i>Anneslea fragrans</i> Wall. (Theaceae)	A07278/LF+TW; A07279/SB	Xiengkhouang MBP
JMH 062	<i>Blumea</i> sp. (Asteraceae)	A07280/PX	Xiengkhouang MBP
JMH 063	<i>Tithonia diversifolia</i> (Hemsl.) A. Gray (Asteraceae)	A07281/LF+TW+FL; A07282/ST	Xiengkhouang MBP
JMH 065	<i>Engelhardia spicata</i> Lesch. ex Bl. (Juglandaceae)	A07283/LF+TW; A07284/SB; A07285/SW	Xiengkhouang MBP
JMH 068	<i>Omphalea bracteata</i> (Blanco) Merr. (Euphorbiaceae)	A07286/ST; A07287/LF+TW	Bolikhambay MPP
JMH 069	<i>Baccaurea ramiflora</i> Lour. (Euphorbiaceae)	A07288/LF+TW; A07289/ST	Bolikhambay MPP
JMH 070	<i>Vitex stylosa</i> Dop (Verbenaceae)	A07290/LF+TW; A07291/ST	Bolikhambay MPP
JMH 071	<i>Ancistrocladus tectorius</i> (Lour.) Merr. (Ancistrocladaceae)	A07292/LF+TW; A07293/ST	Bolikhambay MPP
JMH 072	<i>Lasianthus trichophlebus</i> Hemsl. ex F.B. Forbes & Hemsl. (Rubiaceae)	A07294/LF+TW; A07295/ST	Bolikhambay MPP
JMH 073	<i>Psychotria cephalophora</i> Merr. (Apocynaceae)	A07296/LF+TW; A07297/ST	Bolikhambay MPP
JMH 074	<i>Dracaena cambodiana</i> Pierre ex Gagnep. (Agavaceae)	A07298/LF+TW; A07299/ST	Bolikhambay MPP
JMH 075	<i>Gardenia</i> cf. <i>annamensis</i> Pit. (Rubiaceae)	A07300/LF+TW; A07301/ST	Bolikhambay MPP
JMH 076	<i>Eurycoma longifolia</i> Jack (Simaroubaceae)	A07302/LF+TW; A07303/ST	Bolikhambay MPP
JMH 077	<i>Mussaenda glabra</i> Vahl (Rubiaceae)	A07304/LF+TW; A07305/ST	Bolikhambay MPP
JMH 078	<i>Bauhinia penicilliloba</i> Pierre ex Gagnep. (Fabaceae-Caesalpinioideae)	A07306/LF+TW; A07307/ST	Bolikhambay MPP
JMH 079	<i>Gnetum macrostachyum</i> Hook. f. (Gnetaceae)	A07308/PX	Bolikhambay MPP
JMH 080	<i>Breynia fleuryi</i> Beille (Euphorbiaceae)	A07309/PX	Bolikhambay MPP
JMH 081	<i>Garcinia celebica</i> L. (Clusiaceae)	A07310/LF+TW; A07311/ST	Bolikhambay MPP
JMH 082	<i>Connarus paniculatus</i> Roxb. (Connaraceae)	A07312/LF+TW; A07313/ST	Bolikhambay MPP
JMH 083	<i>Kibatalia laurifolia</i> (Ridl.) Woodson (Apocynaceae)	A07314/LF+TW; A07315/ST	Bolikhambay MPP
JMH 084	<i>Cratoxylum formosum</i> (Jacq.) Benth. & Hook. f. ex Dyer (Clusiaceae)	A07316/ST	Bolikhambay MPP
JMH 085	<i>Knema erratica</i> (Hook. f. & Thomson) J. Sinclair (Myristicaceae)	A07317/LF+TW; A07318/SB; A07319/SW	Bolikhambay MPP
JMH 086	<i>Pterospermum argenteum</i> Tardieu (Sterculiaceae)	A07320/LF+TW; A07321/SB; A07322/SW	Bolikhambay MPP
JMH 087	<i>Arenga caudata</i> (Lour.) H.E. Moore (Arecaceae)	A07323/PX	Bolikhambay MPP
JMH 088	<i>Lithocarpus</i> cf. <i>toumorangensis</i> A. Camus (Fagaceae)	A07324/LF+TW; A07325/SB; A07326/SW	Bolikhambay MPP



Table 1. Cont'd.

JMH 089	<i>Jasminum</i> cf. <i>annamense</i> Wernham ssp. <i>glabrescens</i> P.S.Green (Oleaceae)	A07327/PX	Bolikhaxay MPP
JMH 090	<i>Alpinia calcarata</i> (Haw.) Roscoe (Zingiberaceae)	A07328/LF; A07329/ST; A07330/RT	Bolikhaxay MPP
JMH 091	<i>Amomum</i> cf. <i>villosum</i> Lour. (Zingiberaceae)	A07331/LF; A07332/ST; A07333/RT	Bolikhaxay MPP
JMH 092	<i>Thysanolaena</i> cf. <i>latifolia</i> (Roxb. ex Hornem.) Honda (Poaceae)	A07334/LF; A07335/ST	Bolikhaxay MPP
JMH 093	<i>Cyperus trialatus</i> (Boeckeler) J. Kern (Cyperaceae)	A07336/PL	Bolikhaxay MPP
JMH 094	<i>Millettia pachyloba</i> Drake (Fabaceae-Papilionoideae)	A07337/LF+TW; A07338/ST	Bolikhaxay MPP
JMH 095	<i>Saccharum arundinaceum</i> Retz. (Poaceae)	A07339/PX	Bolikhaxay MPP
JMH 096	<i>Miscanthus</i> cf. <i>sinensis</i> Andersson (Poaceae)	A07340/LF; A07341/ST	Bolikhaxay MPP
JMH 097	<i>Lagerstroemia balansae</i> Koehne (Lythraceae)	A07342/LF+TW; A07343/SB; A07344/SW	Bolikhaxay MPP
JMH 098	<i>Barringtonia pauciflora</i> King (Lecythidaceae)	A07345/LF+TW; A07346/ST	Bolikhaxay MPP
JMH 099	<i>Ormosia cambodiana</i> Gagnep. (Fabaceae-Papilionoideae)	A07347/LF+TW; A07348/SB; A07349/SW	Bolikhaxay MPP
JMH 100	<i>Aporosa ficifolia</i> Baill. (Euphorbiaceae)	A07350/LF+TW; A07351/ST	Bolikhaxay MPP
JMH 101	<i>Ardisia conspersa</i> E. Walker (Myrsinaceae)	A07352/LF+TW+FR; A07353/ST	Bolikhaxay MPP
JMH 102	<i>Securidaca inappendiculata</i> Hassk. (Polygalaceae)	A07354/LF+TW; A07355/ST	Bolikhaxay MPP
JMH 103	<i>Syzygium</i> cf. <i>chloranthum</i> (Duthie) Merr. & L.M.Perry (Myrtaceae)	A07356/LF+TW; A07357/ST	Bolikhaxay MPP
JMH 104	<i>Peltophorum dasyrrhachis</i> (Miq.) Kurz (Fabaceae-Caesalpinioideae)	A07358/LF+TW; A07359/SB; A07360/SW; A07361/RT	Bolikhaxay MPP
JMH 105	<i>Capparis trinervia</i> Hook. f. & Thomson (Capparidaceae)	A07362/ST	Bolikhaxay MPP
JMH 106	<i>Aporosa tetrapleura</i> Hance (Euphorbiaceae)	A07363/LF+TW; A07364/ST	Bolikhaxay MPP
JMH 107	<i>Gardenia annamensis</i> Pit. (Rubiaceae)	A07365/LF+TW; A07366/SB; A07367/SW	Bolikhaxay MPP
JMH 108	<i>Macaranga denticulata</i> (Bl.) Muell.-Arg. (Euphorbiaceae)	A07368/LF+TW; A07369/SB; A07370/SW	Bolikhaxay MPP
JMH 109	<i>Maesa ramentacea</i> (Roxb.) A. DC. (Myrsinaceae)	A07371/LF+TW; A07372/ST	Bolikhaxay MPP
JMH 111	<i>Sandoricum koetjape</i> (Burm.f.) Merr. (Meliaceae)	A07373/LF+TW; A07374/SB; A07375/SW	Bolikhaxay MPP
JMH 112	<i>Tetrameles nudiflora</i> R. Br. (Tetramelaceae)	A07376/LF+TW; A07377/SB; A07378/SW; A07379/RT	Bolikhaxay MPP
JMH 113	<i>Adenanthera pavonina</i> L. (Fabaceae-Mimosoideae)	A07380/LF+TW; A07381/SB; A07382/SW	Bolikhaxay MPP
JMH 114	<i>Fernandoa</i> cf. <i>adenophylla</i> (Wall. ex G. Don) Steenis (Bignoniaceae)	A07383/LF+TW; A07384/ST	Bolikhaxay MPP
JMH 115	<i>Uncaria sinensis</i> (Oliv.) Havil. (Rubiaceae)	A07385/LF+TW; A07386/ST	Bolikhaxay MPP

Plant part abbreviations: FL (flowers); FR (fruits); LF (leaves); PL (whole plant); PX (aerial parts); RT (roots); SB (stem bark); ST (stem); SW (stem wood); TW (twigs). <sup>a</sup>Traditional family names for each species listed are used in this paper; for current family names, please consult Tropicos (<http://www.tropicos.org/>), The Plant List (<http://www.theplantlist.org/>) or APG III (<http://www.mobot.org/MOBOT/research/APweb/>).

(MCF-7) (Soejarto et al., 2002; Kinghorn et al., 2003; Gyllenhaal et al., 2012; Zhang et al., 2016). Of these only HUVEC and hTERT-RPE1 cells are not human tumor cell lines, and only HL-60 is clearly not epithelial in origin. The NCDDG program utilized all of these cell lines as well as a number of additional ones (Kinghorn et al., 2003).

For the cell lines utilized in the ICBG project, the cytotoxicity hit rate for Lao ethnomedical samples from plants ranged between 5 and 9%, with the exceptions of the non-epithelial leukemia cell line HL-60 (1.9%) and the breast cancer cell line MCF-7, as no bioassays were performed with this latter cell line for these samples (Gyllenhaal et al.,

2012). No comparable meta-analysis in relation to the cell lines utilized was produced by the NCDDG, although a synthesis communicated significant insight into potential chemotaxonomic and plant anatomy-based relationships to activity hit rates and levels of cytotoxicity (Balunas et al., 2006).

**Table 2.** Plants from the Xiengkhouang medicinal biodiversity preserve with samples exhibiting notable cytotoxicity in HT-29 colon adenocarcinoma cells.

Species	Active sample (Corresponding voucher specimen)	Plant part(s) active	% HT-29 cell survival (2 µg/mL)	% HT-29 cell survival (20 µg/mL)
<i>Cryptolepis dubia</i>	A07194 (JMH 005)	Stem (ST)	100	48
<i>Rubia argyi</i>	A07196 (JMH 006)	Aerial parts (PX)	69	36
<i>Reevesia pubescens</i>	A07214 (JMH 021)	Fruits (FR)	84	24
<i>Maclura tricuspidata</i>	A07257 (JMH 044)	Leaves, twigs, and fruits (LF+TW+FR)	79	56
<i>Millettia pachyloba</i>	A07338 (JMH 094)	Stem (ST)	77	33
<i>Gardenia annamensis</i>	A07365 (JMH 107)	Leaves and twigs (LF+TW)	100	37

**Table 3.** Comparison of plants and plant parts active with their local employment in traditional medicine.

Active species	Plant part(s) active against HT-29 cells	Lao local name	Plant part(s) used in traditional medicine	Traditional use
<i>Cryptolepis dubia</i>	Stem (ST)	<i>Kheua en one</i>	Liana	Tonic for tendon and muscle
<i>Rubia argyi</i>	Aerial parts (PX)	<i>Kheua lin ma nai</i>	Whole liana	Fever, sore throat, kidney stone
<i>Reevesia pubescens</i>	Fruits (FR)	<i>Mai sa fay</i>	Root, stem	Gastritis
<i>Maclura tricuspidata</i>	Leaves, twigs, and fruits (LF+TW+FR)	<i>Kok nam thaeng</i>	Root	Kidney edema (swollen kidney), tonic for mother after giving birth
<i>Millettia pachyloba</i>	Stem (ST)	<i>Xa kheuy done</i>	Liana	Laxative
<i>Gardenia annamensis</i>	Leaves and twigs (LF+TW)	<i>Khai nao</i>	Stem	Stomachache

### Anticancer bioprospecting from plants: Medical ethnobotany collection, biodiversity-based collection, and the continuum in between

Overall for the Lao ethnomedical plants on a per sample basis, the hit rate for cytotoxicity in cancer cells was higher whereas the “random” plants (from Vietnam) had a higher hit rate on a per collection basis in the ICBG (Gyllenhaal et al., 2012). This disjunction can potentially be explained in part through the fact that ethnomedical plant collection strategy often samples only the plant part used locally whereas the “random” plant collection strategy tends to

sample as many plant parts per plant as can be managed, and therefore “random” collection provides more chances for each taxon to possess a sample bearing activity in one or more bioassays (Spjut, 2005; Gyllenhaal et al., 2012). For our expeditions outlined here overall, for those taxa with collected samples, a little over two (2.09) samples per taxon were obtained, some of which corresponded to plant parts used in local ethnomedicine and others of which did not. Interestingly, 50% (three) of the active samples were from plant parts employed from these taxa ethnomedicinally and the other 50% (three) were from plant parts not used ethno-medically to our knowledge. For each plant that was active, only

one sample out of the 1 to 3 samples collected per taxon demonstrated significant cytotoxicity (Table 3). None of these plants bearing active samples was employed locally to treat cancer. In this context, these facts preliminarily suggest that the strategy of revisiting areas with documented ethnopharmacopeias, collecting as many samples as possible per plant harmonizes the benefits of “random” and ethnobotanical collection strategies for anticancer screening while mitigating their respective downsides.

Richard W. Spjut opines that while cytotoxicity to tumor cell lines and antitumor activity for a plant taxon cannot be known *a priori* based on one reported ethnomedical application versus another,

comparing literature review and ethnopharmacological field work in tandem with biological screening suggests in general that: (a) greater toxicity categories exhibit higher hit rates than all medicinal plants taken as one category and (b) certain categories had three (anthelmintics) to four (arrow poisons and homicidal agents) times the hit rates of plants screened from “random” collections (Spjut, 2005). Still it is not necessarily straightforward that maximizing cytotoxicity in prioritizing bioactive leads always catalyzes advancement in the US pharmaceutical pipeline, as evidenced by the development of anti-hepatitis C nucleoside analogues for instance, which was among the first preclinical pharmacological research to suggest that it may behoove scientists to emphasize leads that retain moderate activity while minimizing toxicity (Sluis-Cremer et al., 2009; Coats et al., 2014). Plants and other sources of bioactive metabolites may be ideally positioned to take advantage of the uncertain interplay between bioactivity and toxicity in the transition from preclinical to clinical evaluation of leads, given that they often produce a suite of closely related analogues. This is particularly salient for plants collected on the basis of use in local medicine, by which their safety for human administration is comparatively and more likely assured in contrast to other sources of bioactive compounds (combinatorial chemistry, microbes, etc.). While as a result of his meta-analysis Spjut furthermore advocates selectively mining medicinal plants for categorical, chemotaxonomic, and/or novelty-related reasons in ongoing screening efforts, he also admits that the faster pace and greater sample collection rate for “random” (biodiversity-based) collection expeditions is attractive (Spjut, 2005). This is interesting because his analysis includes a further admission of the hybridity of collection strategies (Spjut, 2005). This hybridity is bound up in multiple explanations as to why the “random” collection strategy should be punctuated in quotations since, for instance, phytogeography always and chemotaxonomy still often constrain the hit rate results of plants selected for sampling from a given area.

It should be noted that our Lao collection strategy for P01 anticancer screening resembles the pace and sample collection rate of the “random” strategy that Spjut outlines far more than the typical ethnobotany-driven or active sample re-collection expedition in his experience, with an average of ~40/day obtained between the two expeditions, and within the 1 to 3 active samples (out of 60 to 100 acquired) per day projected for a “random” collection effort (Spjut, 2005). This also implies that at the very maximum, a “random” collection effort might be expected to have twice the hit rate of these Lao P01 collection expeditions, while at the low end, such “random” screening could have only a third of the hit rate observed. As with “random” collection expeditions for anticancer screening, chemotaxonomic considerations had an impact on the samples that were collected (Spjut, 2005; Balunas et al., 2006). This principle along with

related inherited wisdom from the National Cancer Institute and the NCDDG/P01 project experience informed our exclusion of certain taxa for sample collection throughout the expeditions. These built-in considerations help demonstrate that this ethnobotanically driven screening strategy implemented for these two Lao expeditions is not an example of ideological purity but rather of hybridity. It would be argued that this eclectic pragmatism contributes to the effectiveness of the innovative strategy as a viable screening paradigm, which is supported perfectly by the fact that twice the number of active hits was generated by broad collection of plant parts as would have been through collection solely of plant parts employed in local ethnomedicine.

### **Prior results and integrative programing in Laos and Vietnam as a predictor of future success and strategic considerations for medicinal plant bio-prospecting**

The expansive and human-centric scope of the Vietnam-Laos ICBG has established and funded infrastructure bolstering traditional medicine through the creation of rural preserves and traditional medicine stations (TMS) in the Lao PDR (Riley, 2001; Sydara et al., 2014; Soejarto et al., 2015); permitted scholarly pursuit of botanical medicines described in Lao palm leaf manuscripts (Elkington et al., 2009); and thoroughly achieved the inventory and preliminary drug discovery lead investigation of the medicinal plants, and the floristic diversity as a whole, in these two countries (Soejarto et al., 2002, 2006, 2012; Sydara et al., 2014). This project's legacy is an exemplar of the fact that medical ethnobotany, alongside such interdisciplinary subfields as historical ecology, landscape archaeology, and political economy (Balée and Erickson, 2006; Campbell, 2007; Scott, 2009), holds human agency intentionality in high esteem, being that they are crucial to value-added applications resulting from examination, discovery, and rediscovery of traditional knowledge. Indeed, human-environment interactions and the cultural transmission of natural and physiological observations are the bedrock underlying the endeavors of medical ethnobotany and ethnopharmacology, ensuring their value in perpetuity (Ott, 1998; Shepard, 2004).

Consideration of past plant collection practices and biological screening results in Vietnam and Laos to date should be able to guide the principles by which future expeditions are performed in the collection of plant samples for the P01 project in the Lao PDR. For instance, in the Vietnam-Laos ICBG, whereas cancer cell cytotoxicity hit rates for “random” samples from Vietnam and ethnomedical samples from the Lao PDR were relatively high, the ethnomedical samples from Vietnam had yielded a low hit rate (Gyllenhaal et al., 2012). It has



been suggested that the differences in these hit rates in ethnobotanical collections between the two countries is attributable to the following factors: (a) a greater proportion of accessions in Laos that were purported correctly by healers to treat cancer in particular and (b) a more specialized knowledge of medicinal properties of flora owing to the Lao healers' greater prominence and mastery (Gyllenhaal et al., 2012). While it has been demonstrated that this study strategy can lead to new bioactive leads for anticancer drug discovery, category-focused ethnobotanical collection for biological screening seemingly is a tractable and rewarding strategy for evaluating the medicinal potential of Lao plant biodiversity as well.

Although no bio-prospecting and isolation work from the Lao PDR has thus far proceeded to the stage of patent filing thereby meriting additional studies (unlike for Vietnam; Zhang et al., 2014, 2017), through the Vietnam-Laos ICBG, six medicinal plant taxa from around the country have been evaluated through the compound isolation stage and have been found to contain mostly novel phytochemicals bearing anti-tuberculosis (Elkington et al., 2014), anti-malarial (He et al., 2005, 2006; Libman et al., 2008; Ma et al., 2008); and cancer cell cytotoxicity activities (Zhang et al., 2004). With respect to anticancer bio-prospecting from the ICBG field work conducted from 1998 to 2012 in the Lao PDR, at least 34 species yielded 50 extracts with significant activity ( $IC_{50} < 20 \mu\text{g/ml}$ ) in one or more cancer cell lines of a six cell line panel, which notably led to the isolated compounds asparacoside and 3''-methoxy-nyasol ( $IC_{50} > 4 \mu\text{g/ml}$ ,  $< 10 \mu\text{g/ml}$ ) from *Asparagus cochinchinensis* (Lour.) Merr. (Soejarto et al., 2012). Integrative research with plants sourced from the network of ten preserves now established in Laos, to search for unanticipated bioactivity, is only in the most incipient of stages. Given adequate resources, biological screening and new active compound discovery from higher plants in these diverse habitats of the Lao PDR could continue indefinitely for decades to come. The link between bio-prospecting results and the biodiversity of these preserves and the country overall is as yet somewhat confounded by the underexplored relationship of abiotic and biotic factors to the phytochemistry of higher plant taxa throughout the monsoon cycle and under local management. These dynamic preserves are liable to yield additional surprises for as long as interdisciplinary programs such as the P01 project are able to support additional expeditions and follow-up research on taxa of interest (Kingham et al., 2009, 2016).

## Conclusions

The two initial P01 expeditions to the Lao PDR demonstrate that biological screening efforts, particularly anticancer bioprospecting, can proceed in areas with

ancient and ongoing cultures of medicinal plant use, with the cooperation of local residents who protect, manage, and depend on the various forest habitats of Laos. Given the unique opportunity for direct collaboration with the Institute of Traditional Medicine (ITM) and some of the authors' involvement with healers and protected areas throughout Laos, it is fully expected that further expeditions will yield comparable or improved results. There are clear reasons why ethnobotanically motivated plant collection in areas rich in medicinal plant reliance can pay greater dividends for drug discovery efforts than other strategies. These rationales stem from the requirements of human safety, minimization of toxicity, and mitigation of related side effect profiles, as well as efficacious pharmacological activity (as vetted by longstanding use by local people), and from the pace of sample collection and turnover of expedition results in terms of the substantial timetables for biological screening and compound isolation work. The Bolikhamxay MPP and Xiengkhouang MBP, which were investigated during the winter dry season, are only two of the ten preserves established in the country. It is hoped that more of such preserves will be established in the future and maintained locally to bolster resilience in medicinal plant resource use and management, ensuring long-term protection of these forested regions throughout Laos.

Far more inventory work and sample collection expeditions to these preserves would be needed to truly exhaust the prospective bioactive leads from these ethnopharmacopeial treasure troves of traditional plant medicine, even for anticancer screening alone. Our interdisciplinary methodology and data analysis produce botanical and phytochemical leads not documented by local plant use patterns, but on the whole and verifiably anticipated by their value in ethnomedicine. The results of this research support the hypothesis that investigating plants known to be employed in local ethnopharmacopeias can produce promising starting points for natural product screening programs and pharmaceutical development, particularly as a first stage for anticancer drug discovery.

## CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

## ACKNOWLEDGEMENTS

The authors wish to acknowledge the guidance of Dr. Yali Fu, who executed an SDCR status application for collections-based research of the National Institutes of Health/National Cancer Institute P01 project (P01CA125066) in the Lao PDR. The status was awarded by the U.S. Department of State on September

9, 2015, which allowed for the collection of voucher specimens and samples in Laos with the collaboration of the Institute of Traditional Medicine, permitting material transfer to and biological evaluation in the USA. They also wish to acknowledge the ethnobotany, pharmacognosy, and chemistry staff of the Institute of Traditional Medicine for their involvement and support in the project. This research could not have proceeded without the broad participation of the ITM staff, and the authors are thankful for their tremendous effort and immense knowledge-base. They also wish to acknowledge the insights and efforts of their workers on these two expeditions, notably Mr. Buasy in the Xiengkhouang MBP and Mr. Bounyong in the Bolikhamxay MPP. Lastly, the participation of officials employed by the Food and Drug Divisions of the Provincial Health Departments of Bolikhamxay and Xiengkhouang was essential for these expeditions to proceed.

## REFERENCES

- Balée WL, Erickson CL (2006). Time and complexity in historical ecology: studies in the neotropical lowlands. Columbia University Press. Available at: <https://cup.columbia.edu/book/time-and-complexity-in-historical-ecology/9780231135627>
- Balunas MJ, Jones WP, Chin YW, Mi Q, Farnsworth NR, Soejarto DD, Cordell GA, Swanson SM, Pezzuto JM, Chai HB, Kinghorn AD (2006). Relationships between inhibitory activity against a cancer cell line panel, profiles of plants collected, and compound classes isolated in an anticancer drug discovery project. *Chem. Biodivers.* 3(8):897-915.
- Bletter N (2007). A quantitative synthesis of the medicinal ethnobotany of the Malinké of Mali and the Asháninka of Peru, with a new theoretical framework. *J. Ethnobiol. Ethnomed.* 3(1):36.
- Campbell DG (2007). A land of ghosts: the braided lives of people and the forest in far western Amazonia. Rutgers University Press. Available at: <https://www.amazon.com/Land-Ghosts-Braided-Western-Amazonia/dp/B005M4RKZW>
- Center for Disease Control (CDC) (2014). Colorectal Cancer Statistics. Available online at: <http://www.cdc.gov/cancer/colorectal/statistics/index.htm>
- Coats SJ, Garnier-Amblard EC, Amblard F, Ehteshami M, Amiralaei S, Zhang H, Zhou L, Boucle SR, Lu X, Bondada L, Shelton JR, Li H, Liu P, Li C, Cho JH, Chavre SN, Zhou S, Mathew J, Schinazi RF (2014). Chutes and ladders in hepatitis C nucleoside drug development. *Antiviral Res.* 102:119-147.
- Elkington BG, Southavong B, Sydara K, Souliya O, Vanthanouvong M, Nettavong K, Thammachack B, Pak DH, Riley MC, Franzblau SG, Soejarto DD (2009). Biological evaluation of plants of Laos used in the treatment of tuberculosis in Lao traditional medicine. *Pharm. Biol.* 47(1):26-33.
- Elkington BG, Sydara K, Newsome A, Hwang CH, Lankin DC, Simmler C, Napolitano JG, Ree R, Graham JG, Gyllenhaal C, Bouamanivong S, Souliya O, Pauli GF, Franzblau SG, Soejarto DD (2014). New finding of an anti-TB compound in the genus *Marsypopetalum* (Annonaceae) from a traditional herbal remedy of Laos. *J. Ethnopharmacol.* 151:903-911.
- Fadeyi SA, Fadeyi OO, Adejumo AA, Okoro C, Myles EL. (2013). In vitro anticancer screening of 24 locally used Nigerian medicinal plants. *BMC Complement. Altern. Med.* 13(1):79.
- Getasetegn M, Tefera Y (2016). Biological Activities and Valuable Compounds from Five Medicinal Plants. *Nat. Prod. Chem. Res.* 4:220.
- Gyllenhaal C, Kadushin MR, Southavong B, Sydara K, Bouamanivong S, Xaiveu M, Xuan LT, Hiep NT, Hung NV, Loc PK, Dac LX (2012). Ethnobotanical approach versus random approach in the search for new bioactive compounds: support of a hypothesis. *Pharm. Biol.* 50(1):30-41.
- He Z-D, Ma C-Y, Sydara K, Bouamanivong S, Zhang H-J, Tan GT, Tames P, Southavong B, Soejarto DD, Pezzuto JM, Fong HHS (2005). Antimalarial Constituents from *Nauclea orientalis* (L.) L. *Chem. Biodivers.* 2(10):1378-1386.
- He ZD, Ma CY, Tan GT, Sydara K, Tamez P, Southavong B, Bouamanivong S, Soejarto DD, Pezzuto JM, Fong HHS, Zhang HJ (2006). Rourinoside and rouramin, antimalarial constituents from *Rourea minor*. *Phytochemistry* 67:1378-1384.
- Kinghorn AD, Farnsworth NR, Soejarto DD, Cordell GA, Swanson SM, Pezzuto JM, Wani MC, Wall ME, Oberlies NH, Kroll DJ, Kramer RA, Rose WC, Vite GD, Fairchild CR, Peterson RW, Wild R (2003). Novel strategies for the discovery of plant-derived anticancer agents. *Pharm. Biol.* 41(Supplement):53-67.
- Kinghorn AD, Carcache de Blanco EJ, Chai HB, Orjala J, Farnsworth NR, Soejarto DD, Oberlies NH, Wani MC, Kroll DJ, Pearce CJ, Swanson SM, Kramer RA, Rose WC, Fairchild CR, Vite GD, Emanuel S, Jarjoura D, Cope FO (2009). Discovery of anticancer agents of diverse natural origin. *Pure Appl. Chem.* 81(6):1051-1063.
- Kinghorn AD, DE Blanco EJ, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, Burdette JE, Swanson SM, Fuchs JR, Phelps MA, Xu L, Zhang X, Shen YY (2016). Discovery of anticancer agents of diverse natural origin. *Anticancer Res.* 36(11):5623-5637.
- Kumar V, Abbas AK, Fausto N, Aster JR (2010). *Cotran pathologic basis of disease*. 2010. Saunders Elsevier, 8th ed. P 784.
- Leonti M, Weckerle CS (2015). Quantitative and comparative methods in ethnopharmacology. In: *Ethnopharmacology*, Heinrich M, Jäger AK (Eds.), Wiley Blackwell. pp. 41-51.
- Libman A, Zhang HJ, Ma CY, Southavong B, Sydara K, Bouamanivong S, Tan GT, Fong HHS, Soejarto DD (2008). An antimalarial steroidal glycoside from *Gongronema napalense*. *Asian J. Tradit. Med.* 3:203-210.
- Ma CY, Musoke SF, Tan GT, Sydara K, Bouamanivong S, Southavong B, Soejarto DD, Fong HHS, Zhang HJ (2008). Study of antimalarial activity of chemical constituents from *Diospyros quaesita*. *Chem. Biodivers.* 5:2442-2448.
- Mazzio EA, Soliman KF (2009). In vitro screening for the tumoricidal properties of international medicinal herbs. *Phytother. Res.* 23(3):385-398.
- Odonne G, Houël E, Bourdy G, Stien D (2017). Treating leishmaniasis in Amazonia: A review of ethnomedicinal concepts and pharmacological analysis of traditional treatments to inspire modern phytotherapies. *J. Ethnopharmacol.* 199:211-230.
- Ott J (1998). The Delphic bee: Bees and toxic honeys as pointers to psychoactive and other medicinal plants. *Econ. Bot.* 52(3):260-266.
- Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989). Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and compare algorithm. *J. Natl. Cancer Inst.* 81(14):1088-1092.
- Pan SY, Zhou SF, Gao SH, Yu ZL, Zhang SF, Tang MK, Sun JN, Ma DL, Han YF, Fong WF, Ko KM (2013). New perspectives on how to discover drugs from herbal medicines: CAM's outstanding contribution to modern therapeutics. *Evid.-Based Complement. Altern. Med.* 2013: 23634172.
- Peruchot M, Forrester K, Almoguera C, Hant K, Grizzle WE (1987). Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. *Nature* 327:298-303.
- Ren Y, Benatrehina PA, Acuña UM, Yuan C, Chai HB, Ninh TN, de Blanco EJ, Soejarto DD, Kinghorn AD (2014). Isolation of bioactive rotenoids and isoflavonoids from the fruits of *Millettia caerulea*. *Planta Med.* 82(11/12):1096-1104.
- Ren Y, Chen W-L, Lantvit DD, Sass EJ, Shriwas P, Ninh TN, Chai H-B, Zhang X, Soejarto DD, Chen X, Lucas DM, Swanson SM, Burdette JE, Kinghorn AD (2017). Cardiac glycoside constituents of *Streblus asper* with potential antineoplastic activity. *J. Nat. Prod.* 80:648-658.
- Riley MC (2000). The Traditional Medicine Research Center (TMRC): A potential tool for protecting traditional and tribal medicinal knowledge

- in Laos. *Cult. Surv. Q.* 24(4):21-24.
- Saslis-Lagoudakis CH, Savolainen V, Williamson EM, Forest F, Wagstaff SJ, Baral SR, Watson MF, Pendry CA, Hawkins JA (2012). Phylogenies reveal predictive power of traditional medicine in bioprospecting. *Proc. Natl. Acad. Sci. U.S.A.* 109(39):15835-15840.
- Scott JC (2009). *The art of not being governed: An anarchist history of upland Southeast Asia.* Yale University Press. Available at: [https://law.yale.edu/system/files/documents/pdf/Intellectual\\_Life/LTW-Scott.pdf](https://law.yale.edu/system/files/documents/pdf/Intellectual_Life/LTW-Scott.pdf)
- Shepard GH (2004). A sensory ecology of medicinal plant therapy in two Amazonian societies. *Am. Anthropol.* 106(2):252-266.
- Shoemaker RH (2006). The NCI60 human tumour cell line anticancer drug screen. *Nat. Rev. Cancer* 6(10):813-823.
- Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF (2009). Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2', 3'-dideoxypurine nucleosides. *Antimicrob. Agents Chemother.* 53(9):3715-3719.
- Soejarto DD, Pezzuto JM, Fong HHS, Tan GT, Zhang HJ, Tamez P, Aydogmus Z, Chien NC, Franzblau SG, Gyllenhaal C, Regalado JC, Hung NV, Hoang VD, Hiep NT, Xuan LT, Hai NV, Cuong NM, Bich TQ, Loc PK, Vu BM, Southavong BH, Sydara K, Bouamanivong S, O'Neill MJ, Lewis J, Dietzman G (2002). An international collaborative program to discover new drugs from tropical biodiversity of Vietnam and Laos. *Nat. Prod. Sci.* 8:1-15.
- Soejarto DD, Fong HHS, Tan GT, Zhang HJ, Ma CY, Franzblau SG, Gyllenhaal C, Riley MC, Kadushin MR, Pezzuto JM, Xuan LT, Hiep NT, Hung NV, Vu BM, Loc PK, Dac LX, Binh LT, Chien NQ, Hai NV, Bich TQ, Cuong NM, Southavong B, Sydara K, Bouamanivong S, Ly HM, Thuy TV, Rose WC, Dietzman GR (2006). Studies on Biodiversity of Vietnam and Laos" 1998-2005: Examining the impact. *J. Nat. Prod.* 69(Special Issue):473-481.
- Soejarto DD, Gyllenhaal C, Kadushin MR, Southavong B, Sydara K, Bouamanivong S, Xaiveu M, Zhang HJ, Rong L, Franzblau SG, Fong HHS, Riley MC, Elkington BG, Waller DP (2012). An ethnobotanical survey of medicinal plants of Laos toward the discovery of bioactive compounds as potential candidates for pharmaceutical development. *Pharm. Biol.* 50(1):42-60.
- Soejarto DD, Elkington BG, Sydara K, Gyllenhaal C, Riley MC, Dietzman GR, Xayvue M, Souliya O, Vanthanouvong M, Southavong B, Kadushin MR, Che C-T (2015). Medicinal plants of Laos: Discoveries, conservation and community engagement – A report submitted to the California Community Foundation. Available at: [http://dds.people.uic.edu/CCF\\_Report\\_20141230.pdf](http://dds.people.uic.edu/CCF_Report_20141230.pdf)
- Spjut RW (2005). Relationships between plant folklore and antitumor activity: An historical review. *SIDA Contrib. Bot.* 21(4):2205-2241.
- Sydara K, Xayvue M, Souliya O, Elkington BG, Soejarto DD (2014). Inventory of medicinal plants of the Lao People's Democratic Republic: A mini review. *J. Med. Plants Res.* 8(43):1262-1274.
- Zhang H-J, Sydara K, Tan G-T, Ma C, Southavong B, Soejarto DD, Pezzuto JM, Fong HHS (2004). Bioactive constituents from *Asparagus cochinchinensis*. *J. Nat. Prod.* 67:194-200.
- Zhang HJ, Soejarto DD, Rong L, Fong HHS, Rumschlag-Booms E, inventors (2014). Aryl naphthalide lignans as anti-HIV agents. International Application Number PCT/US2012/048657, filed July 29, 2012 and published June 4, 2014.
- Zhang HJ, Li WF, Fong HHS, Soejarto DD (2016). Discovery of bioactive compounds by the UIC-ICBG drug discovery program in the 18 years since 1998. *Molecules* 21(11):1448.
- Zhang HJ, Rumschlag-Booms E, Guan YF, Wang DY, Liu KL, Li WF, Nguyen VH, Cuong NM, Soejarto DD, Fong HH, Rong L (2017). Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant *Justicia gendarussa*. *J. Nat. Prod.* 80:1798-1807.